LDS/Medical Tests/Severe Combined Immunodeficiency Gene Panel, NGS

Severe Combined Immunodeficiency Gene Panel, NGS

Severe Combined Immunodeficiency Disorder (SCID) is a group of genetic abnormalities resulting in a severely compromised and dysfunctioning immune system. There is a profound deficiency or even complete absence of T-cells and B-cells diagnostic criteria for SCID are: either a CD3 T-cell number being less than 300/mm3 or an absolute CD3 T cell count of greater than 300/mm3 with absent naïve CD3/CD45RA T cells, and at least one of the following: (a) Male with deleterious pathogenic variant in the X-linked IL2RGgene encoding the cytokine receptor common gamma chain (gamma-c), (b) Male or female patient with deleterious homozygous or compound heterozygous pathogenic variants in any of the genes listed in the Gene Defects table other than IL2RG, (c) ADA activity of less than 2% of control or pathogenic variants in both alleles of the ADA gene, or (d) Engraftment of transplacentally acquired maternal T cells.

Common mutated genes identified in SCID patients include: IL2RG, JAK3, RAG1, RAG2, DCLRE1C, PRKDC, IL7R, CD3D, CD3E, CD247, PTPRC, CORO1A, ADA, AK2, RMRP, NHEJ1, LIG4, PRKDC, LAT, RAC2, TTC7A and RBM8A.

Less commonly, mutations in the following genes have been identified: RFX5, RFXANK, RFXAP, RHOH, SEMA3E, SH2D1A, SLC46A1, STAT5B, STIM1, STK4, TAP1, TAP2, TAPBP, TAZ, TBX1, TNFRSF4(OX40), TRAC, WAS, WIPF1, XIAP(BIRC4), ZAP70, LCK, MAGT1, MALT1, MTHFD1, NFKBIA(IKBA), ORAI1, PNP, and PTPRC(CD45),

It is important to screen neonates for SCID since early death can occur in cases of delayed diagnosis and treatment. The incidence of SCID is 1 in 100,000 births. The symptoms associated with SCID are stunted growth, persistent diarrhea, recurrent bacterial and fungal opportunistic infections. Adolescents with decreasing T-cell counts are also advised to be screened.

  • As and aid in the diagnosis of Severe Combined Immunodeficiency Disorder
  • Therapy selection and monitoring
  • Disease management and surveillance

A positive result indicates the presence of pathogenic variants in the targeted genes. Any detected mutation in any target gene will have its clinical interpretation and indication.

A negative result indicates the absence of pathogenic variants in the targeted genes.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Sanger sequencing, Next-generation sequencing, Massively-parallel sequencing, Polymerase chain reaction.

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: 1 month
Complete blood count (CBC), Differential leukocyte count (DLC), Flow cytometry for T, NK and B lymphocytes and subsets, Peripheral blood smear (PBS), bone marrow analysis, HIV Ab ELISA, T-cell mitogen response, quantitative Ig levels, antibody response to antigens, CD45RO and CD45RA T cell enumeration to detect maternal T cell engraftment.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login